Cancer and hepatic steatosis

ESMO Open

article

R. Paternostro¹  W. Sieghart¹  M. Trauner¹  M. Pinter¹ 

[1] Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna;Liver Cancer ,(HCC) Study Group Vienna, Medical University of Vienna

关键词: non-alcoholic fatty liver disease;    hepatocellular carcinoma;    cancer;    hepatic steatosis;    chemotherapy-induced steatohepatitis;   

DOI  :  10.1016/j.esmoop.2021.100185

学科分类：社会科学、人文和艺术（综合）

来源: BMJ Publishing Group

【 摘 要 】

Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent and increasing liver disease, which encompasses a variety of liver diseases of different severity. NAFLD can lead to liver cirrhosis with all its complications as well as hepatocellular carcinoma (HCC). Steatosis of the liver is not only related to obesity and other metabolic risk factors, but can also be caused by several drugs, including certain cytotoxic chemotherapeutic agents. In patients undergoing liver surgery, hepatic steatosis is associated with an increased risk of post-operative morbidity and mortality. This review paper summarizes implications of hepatic steatosis on the management of patients with cancer. Specifically, we discuss the epidemiological trends, pathophysiological mechanisms, and management of NAFLD, and its role as a leading cause of liver cancer. We elaborate on factors promoting immunosuppression in patients with NAFLD-related HCC and how this may affect the efficacy of immunotherapy. We also summarize the mechanisms and clinical course of chemotherapy-induced acute steatohepatitis (CASH) and its implications on cancer treatment, especially in patients undergoing liver resection.

【 授权许可】

CC BY|CC BY-NC-ND